Trial Profile

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

21 Jul 2023 Status changed from active, no longer recruiting to discontinued.
10 Dec 2019 Planned End Date changed from 31 Mar 2023 to 1 Mar 2023.
10 Dec 2019 Planned primary completion date changed from 31 Mar 2019 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com